Pembrolizumab reactivates pulmonary granulomatosis
Pembrolizumab reactivates pulmonary granulomatosis
复制标题
DOI：
10.1016/j.rmcr.2017.07.010
复制
发表时间：
2017-01-01
影响因子：
1.1
通讯作者：
Shweihat, Yousef
中科院分区：
文献类型：
--
作者：
Al-dliw, Majdi;Megri, Mohammed;Shweihat, Yousef
类肉瘤样反应是一种众所周知的实体，它是几种恶性肿瘤或其治疗的结果。免疫疗法在过去几年中获得了很大的关注，最近已被批准作为多种晚期恶性肿瘤的一线治疗。腹膜炎被描述为这种治疗的并发症。肉芽肿性炎症在免疫治疗后很少报告。我们描述了一例肉芽肿性炎症再激活影响肺部的患者，以前暴露于Pembrolizumab，并有证据表明远处肉芽肿性感染。我们讨论了炎症的潜在机制，并肯定了免疫抑制在控制免疫系统去抑制中的重要性。(C)2017作者由Elsevier Ltd.发布。这是CC BY-NC-ND许可下的开放获取文章。
Sarcoid like reaction is a well-known entity that occurs as a consequence to several malignancies or their therapies. Immunotherapy has gained a lot of interest in the past few years and has recently gained approval as first line therapy in multiple advanced stage malignancies. Pneumonitis has been described as complication of such therapy. Granulomatous inflammation has been only rarely reported subsequent to immunotherapy. We describe a case of granulomatous inflammation reactivation affecting the lungs in a patient previously exposed to Pembrolizumab and have evidence of a distant granulomatous infection. We discuss potential mechanisms of the inflammation and assert the importance of immunosuppression in controlling the dis-inhibited immune system. (C) 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.